Investment Rating - The report assigns a "Buy" rating for the stock, indicating a strong performance relative to the benchmark index [15]. Core Views - The core view emphasizes the stable development of the company's core health examination services, with accelerated progress in transitioning from minority to majority stakes in various subsidiaries, and promising AI applications in health management [2][4][6]. Summary by Sections Company Overview - The company is the largest health examination chain in China, operating four major brands: "Meinian Health," "Ciming Health Examination," "Ciming Aoya," and "Meizhao Health," providing comprehensive and personalized health examination services [2]. Financial Performance - In 2024, the company achieved total revenue of 10.702 billion yuan, a decrease of 1.76% year-on-year. The net profit attributable to shareholders was 282 million yuan, down 44.18% year-on-year [1][8]. - The gross margin for the core health examination services was 42.39%, reflecting a slight increase of 0.33 percentage points year-on-year [3]. Revenue Breakdown - The health examination services generated revenue of 10.331 billion yuan in 2024, with regional contributions from East China (3.599 billion yuan), North China (2.387 billion yuan), South China (1.261 billion yuan), and Central South China (1.348 billion yuan) [2]. - The company served 25.25 million clients in 2024, with a client unit price of 672 yuan, indicating a stable increase [2]. Strategic Initiatives - The company plans to acquire equity stakes in 19 target companies, which are health examination centers, to enhance its service network and market share [4][5]. - The implementation of the "All in AI" strategy aims to leverage health data and AI technology to improve health management services, with projected revenue from AI applications reaching 216 million yuan in 2024 [6]. Future Projections - Revenue forecasts for 2025-2027 are 11.754 billion yuan, 12.910 billion yuan, and 14.180 billion yuan, respectively, with net profits expected to be 612 million yuan, 800 million yuan, and 990 million yuan [8]. - The report anticipates an increase in earnings per share (EPS) from 0.16 yuan in 2025 to 0.25 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 34.33 to 21.23 [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a total revenue of 10.702 billion yuan in 2024, a year-on-year decrease of 1.76%, while the net profit attributable to shareholders was 282.24 million yuan, down 44.18% year-on-year [7] - AI revenue is beginning to scale, with 215.58 million yuan generated from AI-related services, including heart-lung screening and AI for eye and brain health [7] - The company has a stable increase in customer unit price, with an average price of 672 yuan for health check-ups in 2024, reflecting a 4.1 percentage point increase in individual check-up revenue share [7] - The acquisition of 19 health examination centers is expected to enhance the company's performance, contributing approximately 505 million yuan in total revenue and 52 million yuan in net profit for 2024 [7] - The profit forecast for 2025-2026 has been adjusted to 629.21 million yuan and 911.79 million yuan respectively, with a projected net profit of 1.125 billion yuan in 2027, corresponding to PE valuations of 33, 23, and 18 times [7] Summary by Sections Financial Performance - Total revenue for 2024 is projected at 10.702 billion yuan, with a year-on-year growth rate of -1.76% [1] - Net profit attributable to shareholders is expected to be 282.24 million yuan, reflecting a decline of 44.18% year-on-year [1] - The company anticipates a gradual recovery in revenue growth, with projections of 11.587 billion yuan in 2025 and 12.432 billion yuan in 2026 [8] AI and Data Utilization - The company has leveraged its extensive health data, with over 1 billion imaging data points and 200 million structured health data points, to integrate AI technology into its services [7] - The introduction of AI-driven health management tools is expected to reduce service costs and enhance operational efficiency [7] Market Position and Expansion - The company operates 576 health examination centers, with a mix of wholly-owned and joint-venture facilities [7] - The acquisition of additional centers is aimed at solidifying market position and supporting the implementation of AI strategies [7]

中国经济网北京4月15日讯美年健康（002044）(002044.SZ)昨日晚间披露《发行股份购买资产暨关联交 易预案》。 美年健康拟通过发行股份的方式购买交易对方持有的衡阳美年健康体检中心有限公司(简称：衡阳美 年)84.00%股权、宁德美年大健康管理有限公司(简称：宁德美年)81.00%股权、烟台美年大健康体检管 理有限公司(简称：烟台美年)75.00%股权、烟台美年福田健康体检管理有限公司(简称：烟台美年福 田)49.00%股权、武汉美慈奥亚科技管理有限公司(简称：武汉奥亚)52.81%股权、三明美年大健康管理 有限公司(简称：三明美年)85.00%股权、肥城美年健康管理有限公司(简称：肥城美年)90.00%股权、南 宁美元康健康管理有限公司(简称：南宁美元康)69.86%股权、德州美年大健康体检管理有限公司(简 称：德州美年)84.00%股权、安溪美年大健康管理有限公司(简称：安溪美年)72.90%股权、连江美年大 健康管理有限公司(简称：连江美年)82.00%股权、沂水美年大健康体检管理有限公司(简称：沂水美 年)80.50%股权、山东美铭奥亚健康咨询有限公司(简称：山东奥亚)92.35%股权、厦门 ...